Detroit, MINCT07030907Now EnrollingIRB Ready

Ovarian Cancer Recurrent Clinical Trial in Detroit, MI

Access cutting-edge ovarian cancer recurrent treatment through this clinical trial at a research site in Detroit. Study-provided care at no cost to qualified participants.

Sponsored by Outpace Bio, Inc.

Quick Self-Assessment

See if you qualify for this Detroit location

Preparing your pre-screening questions…

Expert Care in Detroit

Access ovarian cancer recurrent specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related ovarian cancer recurrent treatment provided free

Apply for This Detroit Location

Check if you qualify for this ovarian cancer recurrent clinical trial in Detroit, MI

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Detroit

    Convenient for MI residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Detroit site if eligible
  4. 4Begin participation

About This Ovarian Cancer Recurrent Study in Detroit

The goal of this clinical trial is to learn if OPB-101 is safe in platinum resistant ovarian cancer participants and also to find the optimal dose of OPB-101. Participants will have their own T cells modified in a laboratory and given back to them as OPB-101 in this one-time treatment. Participants will be in the hospital when they receive OPB-101 and then be checked at the clinical site frequently for the first few months.

Sponsor: Outpace Bio, Inc.

Who Can Participate

Inclusion Criteria

Age ≥ 18 years of age at the time of signing the informed consent form.
Histologically confirmed diagnosis of high grade serous epithelial ovarian, peritoneal, or fallopian tube cancer based on local histopathological findings.
Recurrent platinum-resistant disease defined as: Disease that has recurred within 6 months of the last receipt of platinum-based therapy.
Received at least 2 prior lines of systemic chemotherapy including a platinum-based chemotherapy.
Received prior therapy with a PARP inhibitor if the subject has a known germline or somatic BRCA1/2 mutation.
Measurable disease.
Consent to provide archived tumor tissue sample.
ECOG performance status of 0 or 1.
Adequate organ function.
Alkaline phosphatase ≤ 2.5 x ULN
≤ Grade 1 dyspnea and oxygen saturation levels (SpO2) \> 92% on room air.
Life expectancy of ≥ 3 months
Adequate venous access.
Negative screen for infectious disease markers.
Negative serum pregnancy test.
Abstain from heterosexual activity or to use 2 forms of effective methods of contraception. Note: Other protocol defined inclusion criteria could apply

Exclusion Criteria

Women of child-bearing potential who are pregnant or breastfeeding.
Uncontrolled bacterial, fungal, or viral infections.
Active infection requiring systemic therapy.
Bleeding or thrombotic disorders or at risk for severe hemorrhage.
Any form of primary immunodeficiency.
Had an allogenic tissue/solid organ transplant.
Active autoimmune disease.
Concurrent treatment with systemic high dose corticosteroids.
Unresolved acute effects of any prior therapy.
Active invasive cancer other than the cancer under study.
Significant lung disease.
Clinically significant pericardial effusion.
Prior radiotherapy within 2 weeks of start of study intervention.
No major surgery within 28 days prior to enrollment.
Received investigational agents or tumor vaccines.
Received chemotherapy within the previous 3 weeks.
History of grade ≥ 3 ascites.
Active CNS involvement.
Received a live vaccine within 30 days prior to study treatment.
Received prior CAR T cell therapy.
Received prior mesothelin targeted therapy.
Dependent on intravenous hydration or total parenteral nutrition. Note: Other protocol defined exclusion criteria could apply

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Detroit?

Yes, this clinical trial (NCT07030907) has an active research site in Detroit, MI that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Ovarian Cancer Recurrent Treatment Options in Detroit, MI

If you're searching for ovarian cancer recurrent treatment options in Detroit, MI, this clinical trial (NCT07030907) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Detroit research site is actively enrolling participants for this clinical trial. You'll receive care from experienced ovarian cancer recurrent specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all ovarian cancer recurrent clinical trials near you to find additional studies recruiting in your area.

More Ovarian Cancer Trials in Detroit, MI

See all ovarian cancer clinical trials recruiting in Detroit — not just this study.

Browse Ovarian Cancer Trials in Detroit →

Browse More Trials by Condition

Ovarian Cancer TrialsAll Conditions →

Ready to Join in Detroit?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Detroit, MI